02:38Senate hearing to examine Ozempic and Wegovy prices
From the creator
Novo Nordisk (NVO) CEO Lars Jørgensen told lawmakers Tuesday he was willing to sit down with pharmacy benefit managers (PBMs) to discuss a lower price for Wegovy and Ozempic, the company's blockbuster weight-loss and diabetes drugs, respectively, in order to expand access to the drugs. The drugs, known as GLP-1s, have brought in $50 billion in revenue for Novo Nordisk year to date alone, but the high prices ($1,349 for Wegovy and $968 for Ozempic) have put them out of reach for many Americans, especially for the weight-loss drugs, due to limited coverage by insurers. For over two hours, Jørgensen faced policymakers led by Sen. Bernie Sanders (I-Vt.) to defend the drugs' prices. On one hand, Jørgensen contends that research and development costs and the rebates paid to PBMs —$0.74 for every dollar — are key parts of a drug's list price. Jørgensen also emphasized that, unlike American pharmaceutical companies, the Danish drugmaker is owned by a large nonprofit "rivaling the Gates Foundation," and therefore, its incentive is not to please shareholders. "I don't think we set our price in a way where we just look at our shareholders," he said. Jørgensen noted that Novo has already discounted the net price of Ozempic by 40% since launching in 2017. About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. For mor
Published 2024-09-24 · Watch on YouTube ↗
Availability and playback restrictions are controlled by the original channel.
Keep exploring News
02:38
02:38
02:06‘Trump’s exit strategy may depend on quietly lifting Iran blockade’ | AJ #shorts
Al Jazeera English
05:26Israeli attacks kill two Palestinians in Gaza as ceasefire violations continue
Al Jazeera English
06:29Brief: Israel's launches first ground operation in Gaza since ceasefire | The Take
Al Jazeera English
01:40
02:02